Opthea said it agreed with the investors in its development funding agreement to end development of sozinibercept in wet AMD, and that the move wouldn't constitute a termination event under the ...

Unity Biotechnology has reported outcomes from its randomised Phase IIb ASPIRE study of intravitreal UBX1325 for diabetic ...

The little hope left for Opthea shareholders has been crushed after the biotech said a second late-stage trial of its eye ...

Intravitreal UBX1325 helped patients with diabetic macular edema gain vision but failed to meet its primary analysis endpoint in the ASPIRE clinical trial, according to a press release from Unity ...

ASX plummets in broad sell-off; gold at new highs; long-time WiseTech chair rejoins board; Todd Sampson exits Qantas; Domain board backs CoStar bid.

UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical ...

Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, ...

Chardan lowered the firm’s price target on Unity Biotechnology (UBX) to $4 from $6 and keeps a Buy rating on the shares after the company ...

Opthea Ltd. is considering its options after lead candidate sozinibercept (OPT-302) failed the phase III Coast trial in wet age-related macular degeneration (AMD). The global Coast phase III trial ...

Kodiak Sciences Inc. , today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "In September of 2024 we hosted an Investor R&D Day ...

Clearside Biomedical advances CLS-AX for wet AMD into Phase 3 trials with FDA alignment, emphasizing flexible dosing and durability.